Nuclear 8-hydroxy-2'-deoxyguanosine as survival biomarker in patients with cutaneous melanoma

  • Authors:
    • Daniela Murtas
    • Franca Piras
    • Luigi Minerba
    • Jorge Ugalde
    • Carlo Floris
    • Cristina Maxia
    • Paolo Demurtas
    • Maria Teresa Perra
    • Paola Sirigu
  • View Affiliations

  • Published online on: February 1, 2010     https://doi.org/10.3892/or_00000640
  • Pages: 329-335
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

8-hydroxy-2'-deoxyguanosine (8-OHdG) is one of the main mutagenic modifications induced in DNA by oxidative stress. Elevated levels of 8-OHdG have been regarded as an independent prognostic factor in different types of cancer. Various enzymes, such as human 8-oxoguanine DNA-glycosylase 1 (hOGG1) and glucose-6-phosphate dehydrogenase (G6PD), act as protection against oxidative stress. The low activity of such enzymes has been consistently associated with increased risk of progression in several tumor types. The aim of this study was to investigate whether 8-OHdG, hOGG1 and G6PD expression in tumor tissues might be a predictor of survival in melanoma patients. The expression of 8-OHdG, hOGG1 and G6PD was immunohistochemically investigated in primary cutaneous melanoma and the effect on survival was analyzed. Furthermore, the immunostaining for p53 and survivin was evaluated and the relationship among 8-OHdG, hOGG1, G6PD, p53 and survivin expression was analyzed. Kaplan-Meier analysis demonstrated that patients with low expression of nuclear 8-OHdG had significantly longer survival time compared with those with a high expression (P=0.032), whereas cancer-specific survival of patients was not associated with hOGG1 or G6PD expression. These results suggest an involvement of oxidative DNA damage in the process of melanoma pathogenesis and demonstrate that 8-OHdG expression in nuclei of tumor cells could be useful as an early independent prognostic marker in patients with primary cutaneous melanoma.

Related Articles

Journal Cover

February 2010
Volume 23 Issue 2

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Murtas D, Piras F, Minerba L, Ugalde J, Floris C, Maxia C, Demurtas P, Perra MT and Sirigu P: Nuclear 8-hydroxy-2'-deoxyguanosine as survival biomarker in patients with cutaneous melanoma. Oncol Rep 23: 329-335, 2010.
APA
Murtas, D., Piras, F., Minerba, L., Ugalde, J., Floris, C., Maxia, C. ... Sirigu, P. (2010). Nuclear 8-hydroxy-2'-deoxyguanosine as survival biomarker in patients with cutaneous melanoma. Oncology Reports, 23, 329-335. https://doi.org/10.3892/or_00000640
MLA
Murtas, D., Piras, F., Minerba, L., Ugalde, J., Floris, C., Maxia, C., Demurtas, P., Perra, M. T., Sirigu, P."Nuclear 8-hydroxy-2'-deoxyguanosine as survival biomarker in patients with cutaneous melanoma". Oncology Reports 23.2 (2010): 329-335.
Chicago
Murtas, D., Piras, F., Minerba, L., Ugalde, J., Floris, C., Maxia, C., Demurtas, P., Perra, M. T., Sirigu, P."Nuclear 8-hydroxy-2'-deoxyguanosine as survival biomarker in patients with cutaneous melanoma". Oncology Reports 23, no. 2 (2010): 329-335. https://doi.org/10.3892/or_00000640